Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function
Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function: From Mice to Children
Philippe Klee, MD-PhD
50 participants
Nov 22, 2024
OBSERVATIONAL
Conditions
Summary
The investigators will measure blood levels of 1,5-anhydroglucitol in obese children with or without type 2 diabetes and correlate them with parameters related to functional beta-cell mass and glucose metabolism. The values will be compared to those obtained in healthy volunteers. The aim of the study is to test the validity of 1,5-anhydroglucitol as a novel biomarker of beta-cell mass and function in children with obesity with or without type 2 diabetes.
Eligibility
Inclusion Criteria3
- Children aged 12 to 16 years
- Obesity. Defined as a body-mass index above the 97th percentile.
- Ability to give informed consent as documented by signature
Exclusion Criteria4
- Patients with diabetes mellitus and positive autoantibodies against islets, insulin, islet antigen 2, glutamic acid decarboxylase or Zinc transporter 8.
- Patients with known liver disease (other than NAFLD)
- Patients treated with an oral antidiabetic drug, glucagon-like peptide-1 analogues or insulin at the time of or less than 2 weeks prior to inclusion.
- Patients treated with a drug known to affect liver function
Interventions
Measurement of blood levels of 1,5-anhydroglucitol
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06682481